Latest Novo Nordisk Stories
Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results
Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation
MISSISSAUGA, ON, June 4, 2014 /CNW/ - Novo Nordisk today announces that the Québec government has approved the inclusion of Victoza(®) (liraglutide), the first once-daily human glucagon-like
Market Size - $4.9 bn in 2013, Market Growth - CAGR of 17.6%, Market Trends – Substitution of human insulin by analogs new report by Grand View Research.
DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs)
LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Changes in preference towards the use of insulin pens will spur double-digit market growth by 2020, reports iData Research Vancouver, BC (PRWEB) April 29, 2014
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
To support continued development of NT100, including addition of Ph2 RESPONSE trial in recurrent pregnancy loss indication PALO ALTO, Calif., April 17, 2014 /PRNewswire/ -- Nora Therapeutics,
Market Size - $20.97 bn in 2013, Market Growth - CAGR of 12.4%, Market Trends – Growing penetration of insulin products in Asian markets.